Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Entrada Therapeutics Inc ( (TRDA) ) just unveiled an announcement.
On February 3, 2025, Entrada Therapeutics announced receiving authorization from the UK’s Medicines and Healthcare Products Regulatory Agency to initiate a Phase 1/2 clinical trial of ENTR-601-44 for Duchenne muscular dystrophy. This trial, set to start in the second quarter of 2025, aims to evaluate the safety, tolerability, and efficacy of ENTR-601-44 in patients amenable to exon 44 skipping, marking a significant step in addressing the medical needs of this patient population with limited treatment options.
More about Entrada Therapeutics Inc
Entrada Therapeutics is a clinical-stage biopharmaceutical company focusing on developing therapies that target intracellular components for various diseases, including neuromuscular, ocular, metabolic, and immunological conditions. Their proprietary Endosomal Escape Vehicle (EEV™)-therapeutics enable effective intracellular delivery of treatments, with a lead focus on developing oligonucleotide programs for Duchenne muscular dystrophy, particularly targeting exon 44, 45, and 50 skipping mutations.
YTD Price Performance: -23.02%
Average Trading Volume: 129,746
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $502.9M
See more data about TRDA stock on TipRanks’ Stock Analysis page.
